RxDoctor Payments Data

Brandie Crawford, APRN

Psychiatric/Mental Health · Pensacola, FLNPI 1194244558

Payments from drug & device makers

$927in general payments, 2019–2025

Across 45 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$232
  • Teva Pharmaceuticals USA, Inc.$115
  • Neurocrine Biosciences, Inc.$108
  • AbbVie$104
  • Johnson & Johnson$78
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$59
  • plus $232 from 8 others

What the payments were for

  • Food & beverage$927100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$927 in reported general payments places this provider in the 55th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$7,471
Medicare patients
37
Services billed
97

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl60$85,017
Abilify MaintenaAripiprazole11$28,190
RexultiBrexpiprazole15$21,755
TrintellixVortioxetine Hydrobromide26$13,264
Fluphenazine Hcl49$7,042
Lurasidone Hcl21$6,768
FetzimaLevomilnacipran Hcl13$6,424
Aripiprazole123$3,986
Quetiapine Fumarate176$2,740
Chlorpromazine Hcl11$2,064
Buspirone Hcl113$1,718
Hydroxyzine Pamoate105$1,481
Trazodone Hcl162$1,415
Duloxetine Hcl44$1,031
Benztropine Mesylate65$1,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Fetzima$104$91,44173 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$232$49,94526 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$54$13,26426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →